Hansa Biopharma AB HNSBF
$3.70 $0.05 (1.37%) 1D
Last Updated: Jul 30, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
HNSBF Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Hansa Biopharma AB is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Hansa Biopharma AB. Stock Analysis HNSBF
United States Health Care Small Cap Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Hansa Biopharma AB (HNSBF) Chart
Financial Metrics & Statements of Hansa Biopharma AB (HNSBF)
FAQ's for Hansa Biopharma AB (HNSBF)
- As of August 2026, Hansa Biopharma AB HNSBF is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hansa Biopharma AB using these criteria to determine its compliance status.
- Muslim investors may consider investing in Hansa Biopharma AB if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Hansa Biopharma AB by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Hansa Biopharma AB may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Hansa Biopharma AB on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Hansa Biopharma AB (HNSBF)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
